|
1
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors-definition, clinical, histological,
immunohistochemical, and molecular genetic features and
differential diagnosis. Virchows Arch. 438:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rubin BP, Singer S, Tsao C, Duensing A,
Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, et al: KIT
activation is a ubiquitous feature of gastrointestinal stromal
tumors. Cancer Res. 61:8118–8121. 2001.PubMed/NCBI
|
|
4
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Demetri GD, von Mehren M, Blanke CD, Van
den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA,
Singer S, Janicek M, et al: Efficacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. N Engl J Med.
347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Le Cesne A, Ray-Coquard I, Bui BN, Adenis
A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A,
et al French Sarcoma Group: Discontinuation of imatinib in patients
with advanced gastrointestinal stromal tumours after 3 years of
treatment: An open-label multicentre randomised phase 3 trial.
Lancet Oncol. 11:942–949. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rusakiewicz S, Semeraro M, Sarabi M,
Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F,
Isambert N, et al: Immune infiltrates are prognostic factors in
localized gastrointestinal stromal tumors. Cancer Res.
73:3499–3510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rubin BP, Heinrich MC and Corless CL:
Gastrointestinal stromal tumour. Lancet. 369:1731–1741. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ménard C, Blay JY, Borg C, Michiels S,
Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF,
et al: Natural killer cell IFN-gamma levels predict long-term
survival with imatinib mesylate therapy in gastrointestinal stromal
tumor-bearing patients. Cancer Res. 69:3563–3569. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borg C, Terme M, Taïeb J, Ménard C,
Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans
K, et al: Novel mode of action of c-kit tyrosine kinase inhibitors
leading to NK cell-dependent antitumor effects. J Clin Invest.
114:379–388. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Perez D, Herrmann T, Jungbluth AA,
Samartzis P, Spagnoli G, Demartines N, Clavien PA, Marino S,
Seifert B and Jaeger D: Cancer testis antigen expression in
gastrointestinal stromal tumors: New markers for early recurrence.
Int J Cancer. 123:1551–1555. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perez D, Hauswirth F, Jäger D, Metzger U,
Samartzis EP, Went P and Jungbluth A: Protein expression of cancer
testis antigens predicts tumor recurrence and treatment response to
imatinib in gastrointestinal stromal tumors. Int J Cancer.
128:2947–2952. 2011. View Article : Google Scholar
|
|
13
|
Ghadban T, Perez DR, Vashist YK, Bockhorn
M, Koenig AM, El Gammal AT, Izbicki JR, Metzger U, Hauswirth F,
Frosina D, et al: Expression of cancer testis antigens CT10
(MAGE-C2) and GAGE in gastrointestinal stromal tumors. Eur J Surg
Oncol. 40:1307–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang GH, Kim KM, Noh JH, Sohn TS, Kim S,
Park CK, Lee CS and Kang DY: WT-1 expression in gastrointestinal
stromal tumours. Pathology. 42:54–57. 2010. View Article : Google Scholar
|
|
15
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ramsay AG: Immune checkpoint blockade
immunotherapy to activate anti-tumour T-cell immunity. Br J
Haematol. 162:313–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
da Silva IP, Gallois A, Jimenez-Baranda S,
Khan S, Anderson AC, Kuchroo VK, Osman I and Bhardwaj N: Reversal
of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
Cancer Immunol Res. 2:410–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leffler H, Carlsson S, Hedlund M, Qian Y
and Poirier F: Introduction to galectins. Glycoconj J. 19:433–440.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heusschen R, Griffioen AW and Thijssen VL:
Galectin-9 in tumor biology: A jack of multiple trades. Biochim
Biophys Acta. 1836:177–185. 2013.PubMed/NCBI
|
|
26
|
Irie A, Yamauchi A, Kontani K, Kihara M,
Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, et al:
Galectin-9 as a prognostic factor with antimetastatic potential in
breast cancer. Clin Cancer Res. 11:2962–2968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van den Brûle F, Califice S and Castronovo
V: Expression of galectins in cancer: A critical review. Glycoconj
J. 19:537–542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang RY and Liu FT: Galectins in cell
growth and apoptosis. Cell Mol Life Sci. 60:267–276. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu FT, Yang RY, Saegusa J, Chen HY and
Hsu DK: Galectins in regulation of apoptosis. Adv Exp Med Biol.
705:431–442. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kobayashi T, Kuroda J, Ashihara E, Oomizu
S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N,
et al: Galectin-9 exhibits anti-myeloma activity through JNK and
p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nobumoto A, Nagahara K, Oomizu S, Katoh S,
Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A and Hirashima
M: Galectin-9 suppresses tumor metastasis by blocking adhesion to
endothelium and extracellular matrices. Glycobiology. 18:735–744.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van Dongen M, Savage ND, Jordanova ES,
Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, Hogendoorn PC, van
der Burg SH, Gelderblom H and van Hall T: Anti-inflammatory M2 type
macrophages characterize metastasized and tyrosine kinase
inhibitor-treated gastrointestinal stromal tumors. Int J Cancer.
127:899–909. 2010.
|
|
34
|
Cameron S, Haller F, Dudas J, Moriconi F,
Gunawan B, Armbrust T, Langer C, Füzesi L and Ramadori G: Immune
cells in primary gastrointestinal stromal tumors. Eur J
Gastroenterol Hepatol. 20:327–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X,
Liu J, Shi L, Liu C, Wang G, et al: Tim-3/galectin-9 signaling
pathway mediates T-cell dysfunction and predicts poor prognosis in
patients with hepatitis B virus-associated hepatocellular
carcinoma. Hepatology. 56:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao
D, Liu Y, Zhu F, Zhang L, Sun W, et al: T cell immunoglobulin - and
mucin-domain-containing molecule-3 (Tim-3) mediates natural killer
cell suppression in chronic hepatitis B. J Hepatol. 52:322–329.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han G, Chen G, Shen B and Li Y: Tim-3: An
activation marker and activation limiter of innate immune cells.
Front Immunol. 4:4492013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hou H, Liu W, Wu S, Lu Y, Peng J, Zhu Y,
Lu Y, Wang F and Sun Z: Tim-3 negatively mediates natural killer
cell function in LPS-induced endotoxic shock. PLoS One.
9:e1105852014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Golden-Mason L, McMahan RH, Strong M,
Reisdorph R, Mahaffey S, Palmer BE, Cheng L, Kulesza C, Hirashima
M, Niki T, et al: Galectin-9 functionally impairs natural killer
cells in humans and mice. J Virol. 87:4835–4845. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gleason MK, Lenvik TR, McCullar V, Felices
M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ,
Panoskaltsis- Mortari A, et al: Tim-3 is an inducible human natural
killer cell receptor that enhances interferon gamma production in
response to galectin-9. Blood. 119:3064–3072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ferris RL, Lu B and Kane LP: Too much of a
good thing? Tim-3 and TCR signaling in T cell exhaustion. J
Immunol. 193:1525–1530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ndhlovu LC, Lopez-Vergès S, Barbour JD,
Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF and
Lanier LL: Tim-3 marks human natural killer cell maturation and
suppresses cell-mediated cytotoxicity. Blood. 119:3734–3743. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Campbell KS and Hasegawa J: Natural killer
cell biology: An update and future directions. J Allergy Clin
Immunol. 132:536–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee KM, Bhawan S, Majima T, Wei H,
Nishimura MI, Yagita H and Kumar V: Cutting edge: The NK cell
receptor 2B4 augments antigen-specific T cell cytotoxicity through
CD48 ligation on neighboring T cells. J Immunol. 170:4881–4885.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mocikat R, Braumüller H, Gumy A, Egeter O,
Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmüller
G, et al: Natural killer cells activated by MHC class I(low)
targets prime dendritic cells to induce protective CD8 T cell
responses. Immunity. 19:561–569. 2003. View Article : Google Scholar : PubMed/NCBI
|
